# Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

> **NCT04345900** · PHASE2 · COMPLETED · sponsor: **BeyondSpring Pharmaceuticals Inc.** · enrollment: 55 (actual)

## Conditions studied

- Chemotherapy-induced Neutropenia

## Interventions

- **DRUG:** Plinabulin
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT04345900
- **Lead sponsor:** BeyondSpring Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-05
- **Primary completion:** 2018-03-20
- **Final completion:** 2018-04-20
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04345900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04345900, "Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04345900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*